Percheron Therapeutics (ASX:PER)
It's a fact of life in the biotech game: drugs often fail in clinical development. Percheron Therapeutics (ASX:PER) had one of those failures late last year. It was working on Avicursen for the treatment of Duchenne Muscular Dystrophy and had reason to believe from earlier work that the drug had potential to…
Kogan shares (ASX:KGN) have been volatile in the past couple of years, but is a better future ahead of it? At first glance, it may not appear a good pick given softening consumer demand, intense competition and negative earnings right now. But the company appears in better shape when you take a deeper dive - arguably…
It is a New Financial Year, so it's time to outline 11 Top ASX Stocks to Buy in FY26. Why 11 you might ask? Because 11 is the number of 'GICS' (Global Industry Classification Sectors) on the ASX, and we're picking one from each sector.
Our 11 Top ASX Stocks to Buy in FY26!
Energy: Ampol…
